1

االسيیرةة االذااتيیةللدكتورر عاددلل بن محمد أأبو ززناددةة

PERSONAL االمعلوماتت االشخصيیة

FULL NAME Dr. Adel Mohammad Abuzenadah ااألسم دد. عاددلل بن محمد محسن أأبوززناددةة DATE OF BIRTH: 28 July 1968 20/5/1388هھھھـ تارريیخ االميیالدد:

NATIONALITY: Saudi سعودديي االجنسيیة: MARITAL STATUS: Married االحالة متزووجج

ااإلجتماعيیة:

!ADDRESS:االعنواانن

Home االمنزلل Work االعمل

P.O. Box 4807 Jeddah 21412 KSA

4807صص.بب. 21412جدةة

االمملكة االعربيیة االسعودديیة

Department of Medical Technology,Faculty of Applied Medical Sciences, KingAbdulazizUniversity P.O. Box 80205Jeddah21589

قسم االتقنيیة االطبيیة, كليیة االعلومم االطبيیة

االتطبيیقيیةجامعة االملك عبد

االعزيیز جدةة 80205صص.بب.

21589

" TELEPHONE:

عمل منزلل

+966 (0)2 2500284

+966 (0)2 640 0000 Ex 21065, 21136 ,

25219

جواالل0504642960

فاكس+966 (0)2 640 0000 Ex. 25227

# E-MAIL aabuzenadah@kau.edu.sa Adel_abuzenadah @hotmail.com

2

CURRENT POSITION: : االحالة االرااهھھھنة

هھھھـ (شعبانن) 1434 االى االوقت االحالي: - ك عبداالعزبزبجامعة االمل عميید كليیة االعلومم االطبيیة االتطبيیقيیة

June 2013 – Until Present Dean, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah. Kingdom of Saudi Arabia.

هھھھـ (صفر) 1434 االى االوقت االحالي: - في االطب االشخصيیبجامعة االملك عبداالعزبزاالتقني مديیر مركز ااإلبتكارر

January 2013– Until Present Director, Center of Innovation in Personalized Medicine, King Abdulaziz University, Jeddah. Kingdom of Saudi Arabia.

هھھھـ ( شعبانن ):1434هھھھـ ( رربيیع أأوولل ) 1432 نائب مديیر مركز االملك فهھد للبحوثث االطبيیة بجامعة االملك عبداالعزيیز

March 2011– June 2013 Vice-Director of King Fahad Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.

هھھھـ ( رربيیع أأوولل ):1432هھھھـ ( صفر ) 1426 بجامعة االمللك عبداالعزبز ووكيیل كليیة االعلومم االطبيیة االتطبيیقيیة

March 2005– February 2011 Vice Dean, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah. Kingdom of Saudi Arabia.

:هھھھـ ( صفر )1426هھھھـ ( ذذوو االقعدةة ) إإلى 1424 ررئيیس قسم تقنيیة االمختبرااتت االطبيیة بكليیة االعلومم االطبيیة االتطبيیقيیة.

January 2004 – Until March 2005 Chairman of Medical Technology Department, Faculty of Applied Medical Sciences.

هھھھـ (ررجب) 1431 االى االوقت االحالي: - أأستاذذ مشارركك في علم أأمرااضض االدمم وو تخثر االدمم وواالوررااثة ٬، قسم االتقنيیة االطبيیة

.كليیة االطب وواالعلومم االطبيیة٬، جامعة االملك عبداالعزيیز

March 2014 - Present Professor of Hematology and Human Genetic, Department of Medical Technology, Faculty of Medicine & Allied Sciences, King Abdulaziz University, Jeddah Kingdom of Saudi Arabia

) رربيیع ثانيهھھھـ (1435 االى االوقت االحالي: -

االتكنولوجيیا االطبيیة٬،أأستاذذ أأمرااضض االدمم وواالجيیناتت االبشريیة٬، قسم .بجامعة االملك عبد االعزيیز ٬،كليیة االطب وواالعلومم االطبيیة

3

February 2010 - March 2014 Associate Professor of Hematology and Human Genetic, Department of Medical Technology Faculty of Medicine & Allied Sciences, King Abdulaziz University, Jeddah. Kingdom of Saudi Arabia.

هھھھـ 1420 : هھھھـ ( ررجب )1431االى - االتقنيیة االطبيیة قسم٬، وو تخثر االدمم وواالوررااثة أأستاذذ مساعد في علم أأمرااضض االدمم

.٬، جامعة االملك عبداالعزيیز (حاليیاً كليیة االعلومم االطبيیة االتطبيیقيیة) كليیة االطب وواالعلومم االطبيیة May 1999 -Until Present Assistant Professor of Hematology and Human Genetic, Department of Medical Technology Faculty of Medicine & Allied Sciences (now: Faculty of Applied Medical Sciences), King Abdulaziz University, Jeddah. Kingdom of Saudi Arabia.

( محرمم ) إإلى االوقت االحالي: 1422 أأحد أأعضاء االفريیق االمسؤوولل عن اانشاء ووحدةة االجيینومم االطبيیةفي مركز االملك فهھـد للبحوثث االطبيیة ووررئيیس قسم ااألحيیاء

االجزيیئة االتشخيیصي في هھھھذهه االوحدةة.Apr. 2001- Until Present An active member of the leading team responsible for establishing the Genomic Medicine Unit (GMU) at King Fahad Medical Research Center and also the Director of the Diagnostic Molecular Section in this unit. EDUCATIONAL BACKGROUND: :االشهھاددااتت االعلميیة

هھھھـ 1411 – 1407 كليیة االطب وواالعلومم االطبيیة جامعة االملك عبد االعزيیز بكالورريیوسس تقنيیة ططبيیة

1987-1991 Faculty of Medicine & Allied Sciences King Abdulaziz University BSc Medical Technology

هھھھـ 1414 – 1413 جامعة شيیفيیلد هھھھلم ووجامعة شيیفيیلد

ماجستيیر علومم ااألمرااضضاالدممتخصص علم أأمرااضض

1993-1994 Sheffield HallamUniversity and Sheffield University MSc Pathological Sciences Specialty Subject: Haematology

هھھھـ 1419 – 1415 جامعة شيیفيیلد

ددكتوررااهه في أأمرااضض االدمم وواالوررااثهھ1994-1998 Sheffield University

PhD in Molecular Hematology Division of Molecular and Genetic Medicine

4

PhD-RESEARCH :

Characterization of the Molecular Basis of Von Willebrand’s Disease.

Clinical Laboratory Experiences:

- Member of the team responsible of developing the Genomic Medicine Unit (GMU) lab at King Fahad Medical Research Center. GMU is now serving patients of King Abdulaziz University Hospital and other near by hospitals. Several specialized laboratory investigations are performed including chromosomal analysis and several molecular testing for various diseases such as qualitative and quantitative analysis of gene fusions in leukemia and detection of mutations causing thrombophilia and other diseases.

- Member of the team responsible of establishing Center of Excellence in Genomic Medicine Research. This center is supported by ministry of higher education and is considered one of a kind in kingdom of Saudi Arabia.

- During PhD research, I have gained experiences in several molecular techniques including different forms of PCR, gel electrophoresis, restriction enzyme analysis, primer design, several mutation detection methods, direct manual and automated DNA sequencing, family studies and cell transfection analysis.

- Several other experiances have been gaind during research and diagnostic work in

molecular and hematology lab such as real time PCR and some of its applications and basic hematology lab analysis such as using cell counters, coagulation tests, and others.

- Recently, I have been involved in setting up research and diagnostic tests using microarray technology and I have received special training on using infinity analyzer produced by Autogenomic, Carlsbad, USA. This is beside new addition of equipment to our lab such as affymetrix system and Agelant system as well ad next generation sequencer from applied biosystems (solid).

ORIGINAL ARTICLES :ااألبحاثث االمنشوررةة

5

1. Khan I, Bangash M, Baeesa S, Jamal A, Carracedo A, Abuzenadah AM et al. Epidemiological trends of histopathologically WHO classified CNS tumors in developing countries: systematic review. Asian Pac J Cancer Prev. 2015;16(1):205-16.

2. Mirza Z, Schulten HJ, Farsi HM, Al-Maghrabi JA, Gari MA, Abuzenadah AM et al. Molecular Interaction of a Kinase Inhibitor Midostaurin with Anticancer Drug Targets, S100A8 and EGFR: Transcriptional Profiling and Molecular Docking Study for Kidney Cancer Therapeutics. PLoS One. 2015;10(3):e0119765.

3. Gari M, Dakhakhni M, Gari A, Alshihri E, Al-Jahdali R, Abuzenadah AM et al. Incidence and potential causative factors associated with chronic benign neutropenia in the Kingdom of Saudi Arabia. BMC Proc. 2015;9(Suppl 2 Selected article from the 2nd International Genomic):S1.

4. Merdad A, Karim S, Schulten HJ, Jayapal M, Dallol A, Abuzenadah AM et al. Transcriptomics profiling study of breast cancer from Kingdom of Saudi Arabia revealed altered expression of Adiponectin and Fatty Acid Binding Protein4: Is lipid metabolism associated with breast cancer?. BMC Genomics. 2015;16 Suppl 1:S11.

5. Marshall CR, Farrell SA, Cushing D, Paton T, Stockley TL, Abuzenadah AM et al. Whole-exome analysis of foetal autopsy tissue reveals a frameshift mutation in OBSL1, consistent with a diagnosis of 3-M Syndrome. BMC Genomics. 2015;16 Suppl 1:S12.

6. Merdad A, Gari MA, Hussein S, Al-Khayat S, Tashkandi H, Abuzenadah AM et al. Characterization of familial breast cancer in Saudi Arabia. BMC Genomics. 2015;16 Suppl 1:S3.

7. Agarwal A, Mulgund A, Alshahrani S, Assidi M, Abuzenadah AM, et al. Reactive oxygen species and sperm DNA damage in infertile men presenting with low level leukocytospermia. Reprod Biol Endocrinol. 2014 Dec 19;12:126.

8. Ali A, Sheikh IA, Mirza Z, Gan SH, Kamal MA, Abuzenadah AM et al. Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders. Curr Drug Metab. 2014 Dec 8.

9. Malvezzi H, Sharma R, Agarwal A, Abuzenadah AM, Abu-Elmagd M. Sperm quality after density gradient centrifugation with three commercially available media: a controlled trial. Reprod Biol Endocrinol. 2014 Dec 2;12:121.

10. Alshahrani S, Agarwal A, Assidi M, Abuzenadah AM, Durairajanayagam D, et al. Infertile men older than 40 years are at higher risk of sperm DNA damage. Reprod Biol Endocrinol. 2014 Nov 20;12:103.

11. Agarwal A, Sharma RK, Sharma R, Assidi M, Abuzenadah AM, et al. Characterizing semen parameters and their association with reactive oxygen species in infertile men. Reprod Biol Endocrinol. 2014 May 7;12:33.

12. Alam MZ, Alam Q, Jiman-Fatani A, Kamal MA, Abuzenadah AM, et al. Candida identification: a journey from conventional to molecular methods in medical mycology. World J Microbiol Biotechnol. 2014 May;30(5):1437-51.

6

13. Rasool M, Malik A, Qazi AM, Sheikh IA, Manan A, Abuzenadah AM et al. Current view from Alzheimer disease to type 2 diabetes mellitus. CNS Neurol Disord Drug Targets. 2014 Apr;13(3):533-42.

14. Karim S, Mirza Z, Kamal MA, Abuzenadah AM, Azhar EI, et al. An association of virus infection with type 2 diabetes and Alzheimer's disease. CNS Neurol Disord Drug Targets. 2014 Apr;13(3):429-39.

15. Alam A, Shaikh S, Ahmad SS, Ansari MA, Shakil S, Abuzenadah AM et al. Molecular interaction of human brain acetylcholinesterase with a natural inhibitor huperzine-B: an enzoinformatics approach. CNS Neurol Disord Drug Targets. 2014 Apr;13(3):487-90.

16. Alam Q, ZubairAlam M, Karim S, Gan SH, Kamal MA, Abuzenadah AM et al. A nanotechnological approach to the management of Alzheimer disease and type 2 diabetes. CNS Neurol Disord Drug Targets. 2014 Apr;13(3):478-86.

17. Sohrab SS, Karim S, Kamal MA, Abuzenadah AM, Chaudhary AG, et al. Bacteriophage--a common divergent therapeutic approach for Alzheimer's disease and type II diabetes mellitus. CNS Neurol Disord Drug Targets. 2014 Apr;13(3):491-500.

18. Aliev G, Shahida K, Gan SH, Firoz C, Khan A, Abuzenadah AM et al. Alzheimer disease and type 2 diabetes mellitus: the link to tyrosine hydroxylase and probable nutritional strategies. CNS Neurol Disord Drug Targets. 2014 Apr;13(3):467-77.

19. Shaik MM, Ahmad S, Gan SH, Abuzenadah AM, Ahmad E, et al. How do periodontal infections affect the onset and progression of Alzheimer's disease?. CNS Neurol Disord Drug Targets. 2014 Apr;13(3):460-6.

20. Alam MZ, Alam Q, Kamal MA, Abuzenadah AM, Haque A. A possible link of gut microbiota alteration in type 2 diabetes and Alzheimer's disease pathogenicity: an update. CNS Neurol Disord Drug Targets. 2014 Apr;13(3):383-90.

21. Chaudhary AG, Hussein IR, Abuzenadah A, Gari M, Bassiouni R, et al. Molecular diagnosis of fragile X syndrome using methylation sensitive techniques in a cohort of patients with intellectual disability. Pediatr Neurol. 2014 Apr;50(4):368-76.

22. Mirza Z, Schulten HJ, Farsi HM, Al-Maghrabi JA, Gari MA, Abuzenadah AM et al. Impact of S100A8 expression on kidney cancer progression and molecular docking studies for kidney cancer therapeutics. Anticancer Res. 2014 Apr;34(4):1873-84.

23. Jabir NR, Kamal MA, Abuzenadah AM, Gan SH, Alama MN, et al. Alzheimer's and type 2 diabetes treatment via common enzyme targeting. CNS Neurol Disord Drug Targets. 2014 Mar;13(2):299-304.

24. Mirza Z, Ali A, Ashraf GM, Kamal MA, Abuzenadah AM, et al. Proteomics approaches to understand linkage between Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets. 2014 Mar;13(2):213-25.

25. Nedjadi T, Haque A, Alam Q, Gan SH, Chaudhary AG, Abuzenadah AM et al. Genomic linkage between Alzheimer's disease and type 2 diabetes. CNS Neurol Disord Drug Targets. 2014 Mar;13(2):203-12.

7

26. Buhmeida A, Dallol A, Merdad A, Al-Maghrabi J, Gari MA, Abuzenadah AM et al. High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast. Tumour Biol. 2014 Mar;35(3):2817-24.

27. Merdad A, Karim S, Schulten HJ, Dallol A, Buhmeida A, Abuzenadah AM et al. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis. Anticancer Res. 2014 Mar;34(3):1355-66.

28. Jamal MS, Parveen S, Beg MA, Suhail M, Chaudhary AG, Abuzenadah AM et al. Anticancer compound plumbagin and its molecular targets: a structural insight into the inhibitory mechanisms using computational approaches. PLoS One. 2014;9(2):e87309.

29. Harakeh S, Diab-Assaf M, Azar R, Hassan HM, Tayeb S, Abuzenadah AM et al. Epigallocatechin-3-gallate inhibits tax-dependent activation of nuclear factor kappa B and of matrix metalloproteinase 9 in human T-cell lymphotropic virus-1 positive leukemia cells. Asian Pac J Cancer Prev. 2014;15(3):1219-25.

30. Karim S, Mirza Z, Kamal MA, Abuzenadah AM, Azhar EI, et al. The role of viruses in neurodegenerative and neurobehavioral diseases. CNS Neurol Disord Drug Targets. 2014;13(7):1213-23.

31. Bibi F, Yasir M, Sohrab SS, Azhar EI, Al-Qahtani MH, Abuzenadah AM et al. Link between chronic bacterial inflammation and Alzheimer disease. CNS Neurol Disord Drug Targets. 2014;13(7):1140-7.

32. Karim S, Mirza Z, Ansari SA, Rasool M, Iqbal Z, Abuzenadah AM et al. Transcriptomics study of neurodegenerative disease: emphasis on synaptic dysfunction mechanism in Alzheimer's disease. CNS Neurol Disord Drug Targets. 2014;13(7):1202-12.

33. Karim S, Mirza Z, Kamal MA, Abuzenadah AM, Al-Qahtani MH. Gene expression analysis approach to establish possible links between Parkinson's disease, cancer and cardiovascular diseases. CNS Neurol Disord Drug Targets. 2014;13(8):1334-45.

34. Abuzenadah AM, Zaher GF, Dallol A, Damanhouri GA, Chaudhary AG, et al. Identification of a novel SBF2 missense mutation associated with a rare case of thrombocytopenia using whole-exome sequencing. J Thromb Thrombolysis. 2013 Nov;36(4):501-6.

35. Qashqari H, Al-Mars A, Chaudhary A, Abuzenadah A, Damanhouri G, et al. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance. Infect Genet Evol. 2013 Oct;19:113-9.

36. Paracha UZ, Fatima K, Alqahtani M, Chaudhary A, Abuzenadah A, et al. Oxidative stress and hepatitis C virus. Virol J. 2013 Aug 7;10:251.

37. Hampshire DJ, Abuzenadah AM, Cartwright A, Al-Shammari NS, Coyle RE, et al. Identification and characterisation of mutations associated with Von Willebrand disease in a Turkish patient cohort. Thromb Haemost. 2013 Aug;110(2):264-74.

38. Tabrez S, Priyadarshini M, Urooj M, Shakil S, Ashraf GM, Abuzenadah AM et al. Cancer chemoprevention by polyphenols and their potential application as

8

nanomedicine. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2013;31(1):67-98.

39. Turki R, Sait K, Anfinan N, Sohrab SS, Abuzenadah AM. Prevalence of human papillomavirus in women from Saudi Arabia. Asian Pac J Cancer Prev. 2013;14(5):3177-81.

40. Abuzenadah AM. The use of Polycomb Gene Targets Methylation as Biomarkers for Hematological Malignancies. World Journal of Medical Services 9 Prev. 2013, no. 4:420-66

41. Kothandaraman N, Gauthaman K, Pushparaj PN, Meenakumari G. Chaudhary AG. Abuzenadah, AM, Gari MA, Al-Qahtani M, Manikandan J. Identification of Unique Mirna Biomarkers in Colorectal Adenoma and Carcinoma Using Microarray: Evaluation of Their Putative Role in Disease Progression. Cell Biology Prev. 2013

42. Mirza Z, Kamal MA, Abuzenadah AM, Al-Qahtani MH, Karim S. Establishing Genomic/Transcriptomic Links between Alzheimer's Disease and Type II Diabetes Mellitus by Meta- Analysis Approach. CNS & neurological disorders drug targets Prev. 2013

43. Dallol A, Al-Maghrabi J, Buhmeida A, Gari MA, Chaudhary AG, Abuzenadah AM et al. Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2069-75.

44. Ali R, Mirza Z, Ashraf GM, Kamal MA, Ansari SA, Abuzenadah AM et al. New anticancer agents: recent developments in tumor therapy. Anticancer Res. 2012 Jul;32(7):2999-3005.

45. Priyadarshini M, Kamal MA, Greig NH, Realef M, Abuzenadah AM, et al. Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):482-9.

46. Shakil S, Kamal MA, Tabrez S, Abuzenadah AM, Chaudhary AG, et al. Molecular interaction of the antineoplastic drug, methotrexate with human brain acetylcholinesterase: a docking study. CNS Neurol Disord Drug Targets. 2012 Mar;11(2):142-7.

47. Begum M, Karim S, Malik A, Khurshid R, Asif M, Abuzenadah AM et al. CA 15-3 (Mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan. Asian Pac J Cancer Prev. 2012;13(10):5257-61.

48. Tabrez S, Jabir, NR, Shakil S, Greig NH, Alam Q, Abuzenadah AM, Damanhouri GA, Kamal MA. A synopsis on the role of tyrosine hydroxylase in Parkinson's disease. CNS & neurological disorders drug targets 11 395-409 Prev. 2012

49. Dallol A, Banni H, Gari M, Al-Qahtani MH, Abuzenadah AM, Chaudhary A, Bidwell JR, Kafienah W. Five novel Glucose-6-Phosphate Dehydrogenase deficiency haplotypes that correlate with disease severity.Journal of Translational Medicine 24;10(1):199. 2012

50. Gari M, Al-Sayes FM, Ahmed F, Peerzada AA, Mira LS, Al-Qahtani M, Dallol A, Abuzenadah AM, Chaudhary A, Mahnashi M, Damanhouri G. JAK2 Mutations

9

in Chronic Myeloproliferative Neoplasm Patients in the Western Regions of Saudi Arabia. Open J Blood Diseases 2, 1-21. 2012

51. Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Abuzenadah AM et al. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Anticancer Res. 2011 Dec;31(12):4179-83.

52. Shakil S, Azhar EI, Tabrez S, Kamal MA, Jabir NR, Abuzenadah AM et al. New Delhi metallo-β-lactamase (NDM-1): an update. J Chemother. 2011 Oct;23(5):263-5.

53. Buhmeida A, Merdad A, Al-Maghrabi J, Al-Thobaiti F, Ata M, Abuzenadah AM et al. RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. Anticancer Res. 2011 Sep;31(9):2975-81.

54. Tabrez S, Shakil S, Urooj M, Damanhouri GA, Abuzenadah AM, et al. Genotoxicity testing and biomarker studies on surface waters: an overview of the techniques and their efficacies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2011 Jul;29(3):250-75.

55. Buhmeida A, Al-Maghrabi J, Merdad A, Al-Thubaity F, Chaudhary A, Abuzenadah AM et al. Prognostic value of mitotic counts in breast cancer of Saudi Arabian patients. Anticancer Res. 2011 Jan;31(1):97-103.

56. Abuzenadah AM, Hussein IM, Damanhouri GA, A-Sayes FM, Gari MA, et al. Molecular basis of β-thalassemia in the western province of Saudi Arabia: identification of rare β-thalassemia mutations. Hemoglobin. 2011;35(4):346-57.

57. Chaudhary AG, Al-Juhani MA, Azam J, Al- Maghrabi J, Gari M, Abuzenadah AM, Al-Qahtani M. Evaluation of Her-2/neu gene amplification in Saudi female breast cancer patients using quantitative real-time PCR and fluorescence in situ hybridization. WASJ, 2011; 14(10):1445-1452

58. Al-Sayes F, Gari M, Qusti S, Bagatian N, Abuzenadah AM. Prevalence of Iron Deficiency and Iron Deficiency Anemia among females at University Stage. Journal of Medical Laboratory and Diagnosis. 2011 Vol 2(1), 5-11

59. Al-Khattabi H, Kelany A, Buhmeida A, Al-Maghrabi J, Lari S, Abuzenadah AM et al. Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization and immunohistochemistry in saudi female breast cancer. Anticancer Res. 2010 Oct;30(10):4081-8.

60. Buhmeida A, Al-Maghrabi J, Merdad A, Al-Thubaity F, Chaudhary A, Abuzenadah AM et al. Nuclear morphometry in prognostication of breast cancer in Saudi Arabian patients: comparison with European and African breast cancer. Anticancer Res. 2010 Jun;30(6):2185-91.

61. Al-Qahtani MH, Baghlab I, Chaudhary AG, Abuzenadah AM, Bamanie A, et al. Spectrum of GJB2 mutations in a cohort of nonsyndromic hearing loss cases from the Kingdom of Saudi Arabia. Genet Test Mol Biomarkers. 2010 Feb;14(1):79-83.

62. Gari MA, Chaudhary AG, Al-Qahtani MH, Abuzenadah AM, Waseem A, et al. Frequency of Mediterranean mutation among a group of Saudi G6PD patients in Western region-Jeddah. Int J Lab Hematol. 2010 Feb;32(1 Pt 2):17-21.

10

63. Abuzenadah AM, Adb Elkader SM, Saiem Aldahr M. Impact of Mild Versus Moderate Intensity Aerobic Exercise Training on Leptin and Selected Innate Immune System Response in Obese Asthmatic Patients.Middle East Journal of Scientific Research 5(1) 2010; 01-05

64. Abuzenadah AM. Association of Specific Structural and Numerical Chromosomal Abnormalities in Lymphoma Cell Lines. Extent of Genetic Instability. Academic Journal of Cancer Research. 2009 2(1); 51-60

65. Gari M, Abuzenadah AM, Chaudhary A, Al-Qahtani M, Banni H, et al. Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis. Int J Mol Sci. 2008 Nov;9(11):2194-204.

66. Ardawi MS, Nasrat HA, Rouzi AA, Qari MH, Al-Qahtani MH, Abuzenadah AM et al. The effect of cigarette or sheesha smoking on first-trimester markers of Down syndrome. BJOG. 2007 Nov;114(11):1397-401.

67. Ardawi MS, Nasrat HA, Rouzi AA, Qari MH, Al-Qahtani MH, Abuzenadah AM et al. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women. Prenat Diagn. 2007 Apr;27(4):303-11.

68. Allen S, Abuzenadah AM, Hinks J, Blagg JL, Gursel T, et al. A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood. 2000 Jul 15;96(2):560-8.

69. Allen S, Abuzenadah AM, Blagg JL, Hinks J, Nesbitt IM, et al. Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood. 2000 Mar 15;95(6):2000-7.

70. Williams IJ, Abuzenadah AM, Winship PR, Preston FE, Dolan G, et al. Precise carrier diagnosis in families with haemophilia A: use of conformation sensitive gel electrophoresis for mutation screening and polymorphism analysis. Thromb Haemost. 1998 Apr;79(4):723-6.

71. Cooper PC, Hampton KK, Makris M, Abuzenadah AM, Paul B, et al. Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency. Br J Haematol. 1994 Sep;88(1):201-3.